Shore Capital is pleased to have acted as Financial Adviser, Nominated Adviser and Joint Broker on Amryt Pharma’s $153m acquisition of Aegerion Pharmaceuticals, Inc. along with a fundraise of $60m in new equity raised from new and existing investors. The acquisition of Aegerion, the operating subsidiary of a NASDAQ-listed pharmaceuticals business, constituted a reverse takeover under the AIM Rules for Companies.
Amryt completed the $60 million fundraise by way of the issue of new Ordinary Shares at a price of $1.79 (approximately £1.44) per Ordinary Share to new and existing investors, and certain stakeholders of Aegerion who backstopped the fundraise.
For further information please contact:
+44 (0) 20 7408 4090
Research: Tara Raveendran
For Shore Capital media enquiries, please contact:
Adele Gilbert: +44 (0)79 6622 4514
Note to editor
About Shore Capital
We are an independent securities business offering institutional and corporate clients leading investment banking, research, sales and trading services, including fixed income. We are represented across the UK enabling extensive distribution and institutional coverage. This distribution capability is complemented by our experienced corporate advisory and broking team who offer discreet, innovative and valued advice to companies on both the Main Market and AIM. Shore Capital is also the 3rd largest market maker by number of AIM stocks covered.
Our cross-disciplinary team has deep, market leading experience in a wide range of small and mid-cap UK companies within the following sectors: Consumer, Financials, Healthcare, Insurance, Natural Resources, Real Estate, Support Services, Technology and Media. Our research on over 250 companies is distributed to an extensive institutional client base in the UK and Europe.
Shore Capital is a trading name of both Shore Capital Stockbrokers Limited and Shore Capital and Corporate Limited.